Eugènia Negredo1, Pere Domingo2, Núria Pérez-Álvarez3, Mar Gutiérrez2, Gracia Mateo2, Jordi Puig1, Roser Escrig1, Patricia Echeverría1, Anna Bonjoch4, Bonaventura Clotet5. 1. Lluita contra la Sida Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain. 2. Santa Creu i Sant Pau Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain. 3. Lluita contra la Sida Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain Statistics and Operations Research Department, Universitat Politècnica de Catalunya, Barcelona, Spain. 4. Lluita contra la Sida Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain abonjoch@flsida.org. 5. Lluita contra la Sida Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain Irsicaixa Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain.
Abstract
BACKGROUND:Tenofovir has been associated with a decrease in bone mineral density (BMD). However, data on changes in BMD after discontinuing tenofovir are lacking. METHODS: We performed a two-centre randomized pilot study in virologically suppressed HIV-infected patients receiving tenofovir with osteopenia/osteoporosis (OsteoTDF study, ClinicalTrials.gov number NCT 01153217). Fifty-four patients were randomly assigned to switch from tenofovir to abacavir (n = 26) or to continue with tenofovir (n = 28). Changes in lumbar and total hip BMD were evaluated at Week 48 from baseline. RESULTS: Five patients discontinued the study (three from the tenofovir group and two from the abacavir group). No significant differences were detected between the groups at Week 48 (P = 0.229 for total hip and P = 0.312 for lumbar spine). However, hip BMD improved by 2.1% (95% CI -0.6 to 4.7) (P = 0.043) in the abacavir group and 0.7% (95% CI -0.9 to 2.4) (P = 0.372) in the tenofovir group. Lumbar spine BMD varied by -0.7% (95% CI -3.8 to 3.3) (P ≤ 0.001) in the abacavir group and -1.2% (95% CI -3.8 to 0.4) (P < 0.001) in the tenofovir group. CONCLUSIONS: Switching from tenofovir to abacavir led to a slight improvement in femoral BMD although no differences were detected between groups. Larger studies are necessary before firm recommendations can be made on the discontinuation of tenofovir in patients with a low BMD.
RCT Entities:
BACKGROUND:Tenofovir has been associated with a decrease in bone mineral density (BMD). However, data on changes in BMD after discontinuing tenofovir are lacking. METHODS: We performed a two-centre randomized pilot study in virologically suppressed HIV-infectedpatients receiving tenofovir with osteopenia/osteoporosis (OsteoTDF study, ClinicalTrials.gov number NCT 01153217). Fifty-four patients were randomly assigned to switch from tenofovir to abacavir (n = 26) or to continue with tenofovir (n = 28). Changes in lumbar and total hip BMD were evaluated at Week 48 from baseline. RESULTS: Five patients discontinued the study (three from the tenofovir group and two from the abacavir group). No significant differences were detected between the groups at Week 48 (P = 0.229 for total hip and P = 0.312 for lumbar spine). However, hip BMD improved by 2.1% (95% CI -0.6 to 4.7) (P = 0.043) in the abacavir group and 0.7% (95% CI -0.9 to 2.4) (P = 0.372) in the tenofovir group. Lumbar spine BMD varied by -0.7% (95% CI -3.8 to 3.3) (P ≤ 0.001) in the abacavir group and -1.2% (95% CI -3.8 to 0.4) (P < 0.001) in the tenofovir group. CONCLUSIONS: Switching from tenofovir to abacavir led to a slight improvement in femoral BMD although no differences were detected between groups. Larger studies are necessary before firm recommendations can be made on the discontinuation of tenofovir in patients with a low BMD.
Authors: David V Glidden; Kathleen Mulligan; Vanessa McMahan; Peter L Anderson; Juan Guanira; Suwat Chariyalertsak; Susan P Buchbinder; Linda Gail Bekker; Mauro Schechter; Beatriz Grinsztejn; Robert M Grant Journal: J Acquir Immune Defic Syndr Date: 2017-10-01 Impact factor: 3.731
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Ann C Collier; Susan L Koletar; Kristine M Erlandson; Michael T Yin; Benedetta Bartali; Belinda Ha; Kathy Melbourne; Todd T Brown Journal: J Infect Dis Date: 2016-06-20 Impact factor: 5.226
Authors: Brenda G Mirembe; Clifton W Kelly; Nyaradzo Mgodi; Susan Greenspan; James Y Dai; Ashley Mayo; Jeanna Piper; Carolyne A Akello; Flavia M Kiweewa; Tsitsi Magure; Clemensia Nakabiito; Jeanne M Marrazzo; Z Mike Chirenje; Sharon A Riddler Journal: J Acquir Immune Defic Syndr Date: 2016-03-01 Impact factor: 3.731
Authors: Patricia Atencio; Francisco Miguel Conesa-Buendía; Alfonso Cabello-Ubeda; Patricia Llamas-Granda; Ramón Pérez-Tanoira; Laura Prieto-Pérez; Beatriz Álvarez Álvarez; Irene Carrillo Acosta; Rosa Arboiro-Pinel; Manuel Díaz-Curiel; Raquel Largo; Gabriel Herrero-Beaumont; Miguel Górgolas; Aránzazu Mediero Journal: Curr HIV Res Date: 2021 Impact factor: 1.341